Factors associated with Medicaid patients' access to buprenorphine treatment
Factors associated with Medicaid patients' access to buprenorphine treatment
复制标题
DOI：
10.1016/j.jsat.2011.02.002
复制
发表时间：
2011-07-01
影响因子：
3.9
通讯作者：
Hashemi, Lobat
中科院分区：
文献类型：
--
作者：
Baxter, Jeffrey D.;Clark, Robin E.;Hashemi, Lobat
一些研究表明，接受丁丙诺啡治疗的患者与接受其他治疗的患者不同。本研究比较了2007年接受丁丙诺啡、美沙酮或其他阿片类药物成瘾治疗的马萨诸塞州医疗补助受益人。通过索赔数据确定患者的特征和合并症，并使用多变量分析研究这些因素与治疗类型之间的关联。在接受阿片受体激动剂治疗的患者中，与美沙酮相比，既往接受过丁丙诺啡治疗、HIV、双相情感障碍和其他物质使用障碍的患者更有可能接受丁丙诺啡治疗，而心力衰竭、糖尿病、丙型肝炎、重度抑郁和焦虑患者接受丁丙诺啡治疗的可能性较小。这些差异可能意味着患者访问、治疗偏好以及不同模式下对不同服务水平的需求存在差异。这些信息对于了解这种新治疗方法对医疗补助人群的影响以及开发最能满足患者需求的治疗系统非常重要。(C)2011 Elsevier Inc. All rights reserved.
Some studies have shown that patients entering buprenorphine treatment differ from those in other modalities. This study compares Massachusetts Medicaid beneficiaries who received buprenorphine, methadone or other treatment for opioid addiction in 2007. Patients' characteristics and comorbidities were identified through claims data, and associations between these factors and treatment type were investigated using multivariate analysis. Among patients receiving opioid agonist treatments, patients with prior buprenorphine treatment, HIV, bipolar disease, and other substance use disorders were more likely to receive buprenorphine treatment compared with methadone, whereas patients with heart failure, diabetes, hepatitis C, major depression, and anxiety were less likely to receive buprenorphine treatment. These differences may suggest variability in patient access, treatment preferences, and a need for different levels of services in different modalities. This information is important for understanding the impact of this new treatment in Medicaid populations and for developing treatment systems to best meet patients' needs. (C) 2011 Elsevier Inc. All rights reserved.